Anti-Viral Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Anti-Viral Therapeutics Market is Segmented by Drug Type (Herpes Anti-Viral Drugs, Hepatitis Anti-Viral Drugs, HIV Anti-Viral Drugs, Influenza Anti-Viral Drugs, and Other Anti-Viral Drugs), Distribution Channel (Hospital Pharmacy, Independent Pharmacy, and Drug Store, Online Pharmacy), and Geography (North America (United States, Canada, and Mexico), Europe ) Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and the Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The Report Offers Value (in USD Million) for the Above Segments.

Anti-Viral Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Anti-Viral Therapeutics Market Size

Anti Viral Therapeutics Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 56.71 Billion
Market Size (2030) USD 62.80 Billion
CAGR (2025 - 2030) 2.06 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Anti-Viral Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Anti-Viral Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Anti-Viral Therapeutics Market Analysis

The Anti-Viral Therapeutics Market size is estimated at USD 56.71 billion in 2025, and is expected to reach USD 62.80 billion by 2030, at a CAGR of 2.06% during the forecast period (2025-2030).

The sudden outbreak of COVID-19 had an optimistic effect on the global anti-viral therapeutics market's growth. The strong market growth due to the COVID-19 pandemic was mainly attributed to the increasing focus of major market players on developing COVID-19 drugs. For instance, in January 2022, Pharma major Lupin launched the antiviral drug Molnupiravir in India under the brand name Molnulup for treating COVID-19 adults in the country. Furthermore, Emcure Pharmaceuticals received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India (DCGI) for launching Molnupiravir to treat mild COVID-19. The company plans to launch the oral drug under the brand Lizuvira in the Indian market. Thus, the market responded to the effect quickly and changed in a way that accelerated market growth.

Similarly, product launches are another factor boosting the growth of the market. For instance, in November 2021, Pfizer Inc. announced its investigational COVID-19 oral antiviral candidate, PAXLOVID, and claimed to significantly reduce hospitalization and mortality rate based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The anti-viral therapeutics market is expected to witness an upsurge mainly due to the increasing patient population in the world. According to WHO, globally, 38.4 million people were living with HIV at the end of 2021. An estimated 0.7% of adults aged 15-49 years worldwide live with HIV; however, the epidemic's burden continues to vary considerably between countries and regions. Thus, with an increase in HIV cases, the need for its therapy increased, leading to market growth.

Moreover, intense research & development pipelines of the major players and increasing product launches are the key drivers in the growth of the antiviral therapeutics market. For instance, in April 2021, Atriva Therapeutics GmbH received USD 12.05 million (EUR 11.4 million) in federal funding. The company will use the funds to advance its drug ATR-002, which is currently in a Phase II clinical study called RESPIRE. Anti-viral therapeutics are commercially available for diseases like influenza, hepatitis C, chickenpox, papilloma, and AIDS.

Thus, the abovementioned factors are impacting the market growth for the anti-viral therapeutics market. However, the high cost of anti-viral drug treatment is expected to restrain the market growth.

Anti-Viral Therapeutics Industry Overview

The anti-viral therapeutics market is moderately competitive. Some of the major players in the anti-viral therapeutics market are AbbVie Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, Merck and Co. Inc. The anti-viral therapeutics market is a fast-growing market. The major players in the market are adopting organic and inorganic strategies to survive and expand. Moreover, the key players are focusing on increasing US Food and Drug Administration (FDA) approvals and product launches to leverage current and future market opportunities.

Anti-Viral Therapeutics Market Leaders

  1. AbbVie Inc.

  2. Bristol-Myers Squibb Company

  3. Gilead Sciences Inc.

  4. F. Hoffman-La Roche Ltd

  5. Cipla Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Anti Viral Therapeutics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Anti-Viral Therapeutics Market News

  • In January 2022, Aurobindo Pharma Limited launched molnupiravir under the brand name Molnaflu for COVID-19 treatment in India. This strengthened the company's product portfolio, thereby creating revenue growth opportunities.
  • In January 2022, Lupin launched the anti-viral drug Molnupiravir in India under the brand name Molnulup to treat adults suffering from COVID-19 in the country.
  • In January 2022, ENTOD Pharmaceuticals launched MOLENTOD in India. The product was made available at affordable prices at retail chemists, pharmacy chains, hospitals, and online stores.

Anti-Viral Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
    • 4.2.2 Increasing Research & Development Investment
    • 4.2.3 Growing Burden of HIV Infection
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Anti-viral Drug Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD million)

  • 5.1 By Drug Type
    • 5.1.1 Herpes Anti-viral Drugs
    • 5.1.2 Hepatitis Anti-viral Drugs
    • 5.1.3 HIV Anti-viral Drugs
    • 5.1.4 Influenza Anti-viral Drugs
    • 5.1.5 Other Drug Types
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacy
    • 5.2.2 Independent Pharmacy and Drug Store
    • 5.2.3 Online Pharmacy
  • 5.3 By Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 AstraZeneca
    • 6.1.3 Boehringer Ingelheim
    • 6.1.4 Bristol-Meyrs Squibb Company
    • 6.1.5 Cipla Inc.
    • 6.1.6 Dr. Reddy's Laboratories Ltd
    • 6.1.7 F. Hoffmann-La Roche Ltd
    • 6.1.8 GlaxoSmithKline PLC
    • 6.1.9 Johnson & Johnson
    • 6.1.10 Merck & Co. Inc.
    • 6.1.11 Novartis AG
    • 6.1.12 Pfizer Inc.
    • 6.1.13 Sanofi SA
    • 6.1.14 Gilead Sciences Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Anti-Viral Therapeutics Industry Segmentation

Anti-viral drugs are a class of medication used for treating viral infections. While a broad-spectrum antiviral is effective against many viruses, most antivirals target specific viruses. 

Anti-viral Therapeutics Market is Segmented by Drug Type (Herpes Anti-viral Drugs, Hepatitis Anti-viral Drugs, HIV Anti-viral Drugs, Influenza Anti-viral Drugs, and Other Anti-viral Drugs), Distribution Channel (Hospital Pharmacy, Independent Pharmacy, and Drug Store, Online Pharmacy), and Geography (North America (United States, Canada, and Mexico), Europe ) Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and the Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers value (in USD billion) for the above segments.

By Drug Type Herpes Anti-viral Drugs
Hepatitis Anti-viral Drugs
HIV Anti-viral Drugs
Influenza Anti-viral Drugs
Other Drug Types
By Distribution Channel Hospital Pharmacy
Independent Pharmacy and Drug Store
Online Pharmacy
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Anti-Viral Therapeutics Market Research FAQs

How big is the Anti-Viral Therapeutics Market?

The Anti-Viral Therapeutics Market size is expected to reach USD 56.71 billion in 2025 and grow at a CAGR of 2.06% to reach USD 62.80 billion by 2030.

What is the current Anti-Viral Therapeutics Market size?

In 2025, the Anti-Viral Therapeutics Market size is expected to reach USD 56.71 billion.

Who are the key players in Anti-Viral Therapeutics Market?

AbbVie Inc., Bristol-Myers Squibb Company, Gilead Sciences Inc., F. Hoffman-La Roche Ltd and Cipla Inc. are the major companies operating in the Anti-Viral Therapeutics Market.

Which is the fastest growing region in Anti-Viral Therapeutics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Anti-Viral Therapeutics Market?

In 2025, the North America accounts for the largest market share in Anti-Viral Therapeutics Market.

What years does this Anti-Viral Therapeutics Market cover, and what was the market size in 2024?

In 2024, the Anti-Viral Therapeutics Market size was estimated at USD 55.54 billion. The report covers the Anti-Viral Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Anti-Viral Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Anti-Viral Therapeutics Industry Report

The global antiviral drugs market is experiencing dynamic shifts influenced by various market segments and trends. The persistent prevalence of viral diseases such as HIV, hepatitis, and influenza continues to drive the need for effective treatments. The market is segmented into branded and generic drugs, with branded drugs currently leading due to their established efficacy and safety profiles. However, the generic segment is anticipated to grow rapidly, driven by the demand for more affordable medication options in developing regions. Significant research and development activities are leading to the approval and commercialization of novel antiviral drugs, supported by strategic collaborations among key market players and research institutions. Yet, the high cost of antiviral drugs remains a major barrier, particularly in low- and middle-income countries. For a detailed analysis of the anti-viral drugs market size, share, revenue growth rate, and a forecast outlook, download a free report PDF from Mordor Intelligence™ Industry Reports. This comprehensive overview will benefit anti-viral drugs market companies navigating through innovation, regulation, and market competition challenges.